Estudo comparativo entre rivaroxaban e enoxaparina na profilaxia de tromboembolismo venoso profundo em pacientes submetidos à artroplastia total do quadril

Kanan, Pedro Silva; Schwartsmann, Carlos Roberto; Boschin, Leonardo Carbonera; Conrad, Samuel; Silva, Marcelo Faria

doi:10.1590/s0102-36162008000800002

Cited by 15 publications

(18 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…patient population (with 20 associated references [153][154][155][158][159][160][164][165][166]174,176,177,179,181,183,186,189,[192][193][194] ), 17 trials in knee surgery patient population (with 18 associated references 152,156,157,[161][162][163][167][168][169][171][172][173]175,178,180,182,187,196 ), seven trials in medical patient population (with seven associated references 170,184,185,188,190,191,197 ) and one trial (with one associated reference 195 ) involving both hip and knee surgery patients. Thirty-nine of the trials were multicentre and four were single-centre trials.…”

Section: Figure 32mentioning

confidence: 99%

Oral anticoagulants for primary prevention, treatment and secondary prevention of venous thromboembolic disease, and for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis and cost-effectiveness analysis

Sterne

Bodalia

Bryden

et al. 2017

Health Technol Assess

124

175

View full text Add to dashboard Cite

outside the submitted work, and AntiCoagulation Europe (ACE), a registered charity, the aims of which include raising awareness of the risk and prevention of thrombosis, and providing information, education and support to people who are on anticoagulation therapy for any duration, including long term for those with chronic conditions. Diane Eaton works with ACE in an associate consultant capacity in the role of Project Development Manager. She has over 40 years of personal experience of anticoagulation therapy and represents ACE as a patient expert at the National Institute for Health and Care Excellence (NICE). On behalf of the charity, she has provided the patient perspective for the submissions for the technology appraisals for the novel oral anticoagulants (NOACs) and Diagnostic Guidance for Coagulometers over a 4-year period. Please note that the financial information has been prepared by Eve Knight, Chief Executive of AntiCoagulation Europe, for the purpose of inclusion in this document. Published March 2017 DOI: 10.3310/hta21090This report should be referenced as follows:Sterne JAC, Bodalia PN, Bryden PA, Davies PA, López-López JA, Okoli GN, et al. Oral anticoagulants for primary prevention, treatment and secondary prevention of venous thromboembolic disease, and for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis and cost-effectiveness analysis. Health Technol Assess 2017;21(9). Reports are published in Health Technology Assessment (HTA) if (1) they have resulted from work for the HTA programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors. Health Technology Assessment is indexed and abstracted inReviews in Health Technology Assessment are termed 'systematic' when the account of the search appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others. HTA programmeThe HTA programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care.The journal is indexed in NHS Evidence via its abstracts included in MEDLINE and its Technology Assessment Reports inform National Institute for Health and Care Excellence (NICE) guidance. HTA research is also an important source of evidence for National Screening Committee (NSC) policy decisions.For more information about the HTA programme please visit the website: http://www.nets.nihr.ac.uk/programmes/hta This reportThe research reported in this issue of the journal was funded by the HTA programme as project number 11/92/17. The contractual start date was in October 2013. The draft report began editorial review in May 2015 and was accepted for publication in...

show abstract

Section: Figure 32mentioning

confidence: 99%

Oral anticoagulants for primary prevention, treatment and secondary prevention of venous thromboembolic disease, and for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis and cost-effectiveness analysis

Sterne

Bodalia

Bryden

et al. 2017

Health Technol Assess

124

175

View full text Add to dashboard Cite

show abstract

“…The studies presented different results in all variables considered. Table 1 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 demonstrates that the most studied oral anticoagulant was rivaroxaban, followed by the antiplatelet agent Aspirin ® and dabigatran.…”

Section: Resultsmentioning

confidence: 99%

“… Low incidence of thrombosis and safe to use in thromboprophylaxis. Kanan et al, 2008 12 Intervention 33 Rivaroxaban 10 mg 32–36 days 3 cases of DVT (phlebography 32–36 PO). No cases of PE or major bleeding.…”

Section: Resultsmentioning

confidence: 99%

Use of oral anticoagulants for the prevention of thromboembolic events in the post-operative period of hip arthroplasty: a systematic review

Trevisol

Coppi

Pancotte

et al. 2018

Revista Brasileira de Ortopedia (English Edition)

View full text Add to dashboard Cite

Oral anticoagulants are being used in the postoperative period of hip arthroplasty to prevent of thromboembolic events, create doubts as to the effectiveness of thromboprophylaxis and reduce the risk of hemorrhage. This systematic revision is aimed at evaluating the use of oral anticoagulants in the prevention of thromboembolic events in the postoperative period of patients undergoing hip arthroplasty. Research with descriptors found on PubMed, BVS, and the CAPES portal for medical journal publications from September 2015 to June 2016, from the last ten years (2005–2015), complete, free, and written in Portuguese and in English were the methods used. The results of the studies showed some cases of pulmonary embolism, deep vein thrombosis, and bleeding; even then, the NOACs were effective in preventing thromboembolic events. There is no consensus regarding the prophylaxis method for these events, which is why the challenge is to obtain high levels of prevention while minimizing the adverse effects. The most studied oral anticoagulant was rivaroxaban (67%). The three drugs that were studied have shown to be effective in preventing thromboembolic events, but the best results were obtained with rivaroxaban 10 mg, one tablet daily; treatment duration ranged from 30 to 35 days with oral anticoagulants and from 28 to 42 days with anti-platelet drugs.

show abstract

“…Twenty-two studies were included, of which 10 came from AOB 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 and 12 from RBO 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 ( Table 1 ). Evaluation of the inter-observer reliability (S1 and S2) for the Jadad score resulted in a kappa value of 0.611 (substantial, excellent).…”

Section: Resultsmentioning

confidence: 99%

Randomized Controlled Trials in Orthopedics and Traumatology: Systematic Analysis on the National Evidence

Moraes

Moreira

Tamaoki

et al. 2010

Revista Brasileira de Ortopedia (English Edition)

View full text Add to dashboard Cite

Objective: To assess whether there has been any improvement in the quality and quantity of randomized controlled trials (RCTs) in nationally published journals through the application of standardized and validated scores. Methods: We electronically selected all RCTs published in the two indexed Brazilian journals that focus on orthopedics, over the period 2000-2009: Acta Ortopédica Brasileira (AOB) and Revista Brasileira de Ortopedia (RBO). These RCTs were identified and scored by two independent researchers in accordance with the Jadad scale and the Cochrane Bone, Joint and Muscle Trauma Group score. The studies selected were grouped as follows: 1) publication period (2000-2004 or 2004-2009); 2) journal of publication (AOB or RBO). Results: Twenty-two papers were selected: 10 from AOB and 12 from RBO. No statistically significant differences were found between the proportions (nRCT/nTotal of published papers) of RCTs published in the two journals (p = 0.458), or in the Jadad score (p = 0.722) and Cochrane score (p = 0.630). Conclusion: The relative quality and quantity of RCTs in the journals analyzed were similar. There was a trend towards improvement of quality, but there was no increase in the number of RCTs between the two periods analyzed.

show abstract

Estudo comparativo entre rivaroxaban e enoxaparina na profilaxia de tromboembolismo venoso profundo em pacientes submetidos à artroplastia total do quadril

Cited by 15 publications

References 30 publications

Oral anticoagulants for primary prevention, treatment and secondary prevention of venous thromboembolic disease, and for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis and cost-effectiveness analysis

Oral anticoagulants for primary prevention, treatment and secondary prevention of venous thromboembolic disease, and for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis and cost-effectiveness analysis

Use of oral anticoagulants for the prevention of thromboembolic events in the post-operative period of hip arthroplasty: a systematic review

Randomized Controlled Trials in Orthopedics and Traumatology: Systematic Analysis on the National Evidence

Contact Info

Product

Resources

About